NDAORALTABLETPriority Review
Approved
Dec 1985
Lifecycle
LOE Approaching
Competitive Pressure
60/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VASOTEC (enalapril maleate) is an oral ACE inhibitor approved in 1985 for hypertension management. It works by inhibiting angiotensin-converting enzyme, reducing angiotensin II production and decreasing vasopressor activity and aldosterone secretion. The drug is effective across racial populations, though black patients with low-renin hypertension show smaller average response to monotherapy.
$0.003BPart D
LOE ApproachingDeclining
Declining Part D utilization signals mature market with generic competition; brand team focus is on managing transition and maintaining niche positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VASOTEC offers limited career growth given LOE trajectory and minimal commercial spending ($3M Part D). Roles would be primarily defensive (managing generic conversion, maintaining market share in niche segments) rather than growth-oriented.
Company
Worked on VASOTEC at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.